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Abstract 
Eighty percent of lung cancers originate as subtle premalignant changes in the airway mucosal epithelial 
layer of bronchi and alveoli, which evolve and penetrate deeper into the parenchyma. Liquid-ventilation, 
with perfluorocarbons (PFC) was first demonstrated in rodents in 1966 then subsequently applied as 
lipid-encapsulated PFC emulsions to improve pulmonary function in neonatal infants suffering with 
respiratory distress syndrome in 1996. Subsequently, PFC nanoparticles (NP) were extensively studied as 
intravenous (IV) vascular-constrained nanotechnologies for diagnostic imaging and targeted drug delivery 
applications.  
Methods: This proof-of-concept study compared intratumoral localization of fluorescent paramagnetic 
(M) PFC NP in the Vx2 rabbit model using proton (1H) and fluorine (19F) magnetic resonance (MR) 
imaging (3T) following intratracheal (IT) or IV administration. MRI results were corroborated by 
fluorescence microscopy.  
Results: Dynamic 1H-MR and 19F-MR images (3T) obtained over 72 h demonstrated marked and 
progressive accumulation of M-PFC NP within primary lung Vx2 tumors during the first 12 h post IT 
administration. Marked 1H and 19F MR signal persisted for over 72 h. In contradistinction, IV M-PFC NP 
produced a modest transient signal during the initial 2 h post-injection that was consistent circumferential 
blood pool tumor enhancement. Fluorescence microscopy of excised tumors corroborated the MR 
results and revealed enormous intratumor NP deposition on day 3 after IT but not IV treatment. 
Rhodamine-phospholipid incorporated into the PFC nanoparticle surfactant was distributed widely 
within the tumor on day 3, which is consistent with a hemifusion-based contact drug delivery mechanism 
previously reported. Fluorescence microscopy also revealed similar high concentrations of M-PFC NP 
given IT for metastatic Vx2 lung tumors. Biodistribution studies in mice revealed that M-PFC NP given IV 
distributed into the reticuloendothelial organs, whereas, the same dosage given IT was basically not 
detected beyond the lung itself. PFC NP given IT did not impact rabbit behavior or impair respiratory 
function. PFC NP effects on cells in culture were negligible and when given IV or IT no changes in rabbit 
hematology nor serum clinical chemistry parameters were measured.  
Conclusion: IT delivery of PFC NP offered unique opportunity to locally deliver PFC NP in high 
concentrations into lung cancers with minimal extratumor systemic exposure. 










Lung cancer is a leading cancer killer in both 
men and women in the US, in recent years surpassing 
breast cancer to become the leading cause of cancer 
death in women. Worldwide, lung cancer is the most 
common malignancy with ~1.8 million new cases and 
1.6 million deaths annually [1]. Unfortunately, the 
five-year survival rate for lung cancer (17.8%) is 
notably less than for malignancies in the colon 
(65.4%), breast (90.5%) and prostate (99.6%) [2]. While 
patients diagnosed with early stage lung cancer have 
~50% 5-year survival rate, the majority of individuals 
are diagnosed late and are dead within a year. This 
poor prognosis reflects the late presentation of clinical 
disease symptoms, including cough, hemoptysis, 
dyspnea, chest pain, or non-resolving pneumonia, 
that prompt patients to seek medical attention. Most 
lung cancer patients are diagnosed with non-small 
cell lung cancer (NSCLC) (87%) with the remaining 
malignancies attributed to small cell lung cancer [3]. 
80% of lung cancers originate as premalignant 
changes in the airway mucosal epithelial layer of 
bronchi and alveoli that progressively infiltrate into 
the underlying parenchyma [4]. Clinically silent, these 
small early lesions are typically beyond the resolution 
of computed tomography (CT), magnetic resonance 
(MR) or positron emission tomography/CT (PET/CT) 
to detect effectively.18F-fluorodeoxyglucose PET 
screening for lung cancer has a central role in disease 
staging and therapeutic response assessment, but the 
technique’s diagnostic sensitivity is only 83% [5, 6]. 
Optical imaging via bronchoscopy is effective for 
evaluating premalignant epithelial mucosal lesions in 
the central airways, but the invasive technique can 
only interrogate six to seven generations of bronchi 
with the thinnest bronchoscopes [7], leaving the outer 
two-thirds of the lung inaccessible [8]. 
Traditional 1H MRI is plagued by respiratory 
motion, air-tissue chemical-shift artifacts, and a low 
prevalence of tissue water protons when imaging the 
lung. However, promising advancements in MR 
pulmonary imaging using simultaneous proton and 
fluorine (1H/19F) MRI with ultrashort echo time 
sequences (UTE) have been implemented for 
preclinical models using clinical 3T MR scanners [9]. 
These emergent techniques optimized 19F imaging 
and quantification by simultaneously acquiring 
proton and fluorine image data, allowing the more 
robust proton information to be used to optimize coil 
and power parameters and to correct for motion 
artifacts [9-11]. These technology advances have 
brought the opportunity for high-resolution, 
non-invasive, nonionizing MR imaging of the lung 
closer to the clinic. 
Perfluorocarbon (PFC) nanoparticles (NP) are 
~98% PFC with a high fluorine concentration of ~100 
M [12]. Early preclinical and later clinical research 
with PFCs involved liquid breathing, taking 
advantage of the high oxygen-dissolving capacity of 
PFCs to overcome respiratory distress in preterm 
babies due to natural surfactant deficiencies [13-15]. 
Although PFC NP emulsions were clinically effective 
in neonates for this application, alternative surfactant 
replacement technologies soon emerged and 
supplanted their use [16, 17]. Cognizant of the 
oxygen-dissolving capacity and high biocompatibility 
of PFC emulsions, other investigators continued the 
clinical development of PFC NP as artificial blood 
substitutes [18]. During this timeframe, PFC NP 
research expanded to include GI bowel and general 
blood pool contrast uses for CT, MRI, and Doppler 
ultrasound [19-23]. 
The present research considers for the first time 
the use of PFC NP administered IT for diagnostic MR 
imaging of lung cancer in the Vx2 rabbit model. Given 
the high biocompatibility and liquid ventilation 
history of perfluorocarbon emulsions, the overarching 
hypothesis considered was whether prolonged IT 
exposure of lung cancers to PFC NP would afford 
deep locally-confined tumor penetration and strong 
1H/19F MR signal. The objectives of this study were to: 
1) demonstrate that PFC NP can be safely 
administered via IT delivery into rabbits with Vx2 
lung cancer, 2) measure tumor temporal spatial 
differences in 1H T1 mapping and 19F MR imaging 
following IT vs. IV delivery of PFC NP with a 
clinically relevant scanner, 3) microscopically 
characterize PFC NP retention and distribution in 
tumor versus normal lung tissue regions, and 4) 
compare the biodistribution and bioelimination 
pathways of PFC NP given IT versus IV.  
Materials and Methods 
Chemicals 
Unless otherwise listed, all solvents and reagents 
were purchased from Aldrich Chemical Co. and used 
as received. Phospholipids were purchased from 
Avanti Polar Lipids, Inc. (Alabama, USA). Argon gas 
(Ultra High Purity: UHP, 99.99%) was used to reduce 
oxidation of lipid materials and nanoparticle 
emulsions. Dialysis was performed with Spectra/Por 
membranes (Cellulose MWCO: 20,000 D, Spectrum 
Medical Industries, Inc.) Perfluoro-15-crown-5 ether 
(PFCE, C10F20O5) was purchased from Exfluor 
Research Corporation (Round Rock, TX) and used as 
acquired. 





Preparation of multifunctional 
perfluorocarbon nanoparticles 
Multifunctional paramagnetic PFC NP (M-PFC 
NP) incorporating a fluorescent lipid-anchored dye 
were synthesized using microfluidization similar to 
prior reports [24-26]. Briefly, the nanoparticulate 
emulsions were comprised of 20% (v/v) PFCE, 2% 
(w/v) of a surfactant commixture, 1.7% (w/v) 
glycerin and water representing the balance. The 
surfactant included 80 mol% dipalmitoyl 
phosphatidylcholine (DPPC), 10 mol% cholesterol, 5 
mol% Gd-DTPA-phosphatidylethanolamine (Gd- 
DTPA-DPPE), 0.1 mol% 1,2-dipalmitoyl-sn-glycero-3- 
phosphoethanolamine-N-(lissaminerhodamine B 
sulfonyl) (ammonium salt) (16:0 LissRhod PE), and 4.9 
mol%1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-gl
ycerol) (sodium salt). The lipids were dissolved in a 
mixture of methanol and chloroform, filtered through 
a small bed of cotton, evaporated under reduced 
pressure using a rotary evaporator at 45 °C to form a 
thin film, and then further dried in a vacuum oven (45 
°C) for 24 h. The resuspended surfactant was 
combined with PFCE and water, then emulsified in a 
M110P Microfluidics emulsifier (Microfluidics, 
Newton, MA) at 20,000 psi for 4 min. The products 
were dialyzed against deionized water using a 20 kDa 
MWCO cellulosic membrane. The completed 
emulsions were placed in crimp-sealed vials, 
blanketed with argon, and stored at 4 °C until use. 
Physical and chemical characterization of 
nanoparticles  
Hydrodynamic diameter distribution, 
polydispersity, and zeta potential (ζ) of the PFC 
nanoparticles were determined by dynamic light 
scattering (DLS) with a Malvern Nano ZS Zetasizer 
(Malvern Instruments Ltd, Malvern, UK). All 
determinations were made in multiples of five 
consecutive measurements. Measurements of ζ were 
reproducible to within ±4 mV of the mean value given 
by 16 determinations of 10 data accumulations. 
Atomic force microscopy measurements (AFM, 
Bruker Dimension Icon) were executed in standard 
tapping mode. UV/Vis absorption spectra were 
performed on a calibrated spectrophotometer 
(Perkin-Elmer Lambda 35) at room temperature.  
The dissolved oxygen (O2) and the release rate of 
O2 in pure water and perfluorocarbon (20% v/v) 
solution were measured with a digital multi 
parameter meter (Multi 3430 WTW, Germany) 
coupled to an O2 sensor (CellOx 325, WTW, 
Germany). Pre-test, the samples were ventilated with 
slowly bubbling O2 for a predetermined duration. The 
measurements of the release rate of oxygen were 
performed with O2 ventilation for 5 min, then airflow 
was arrested and O2 content was analyzed at baseline 
and every 5 min for 60 min thereafter.  
Cellular toxicity of perfluorocarbon 
nanoparticles on bronchial epithelium  
The cell viability of normal human bronchial 
epithelium BEAS-2B cells (ATCC® CRL-9609™, 
Manassas, VA) and lung cancer H520 cells (ATCC® 
HTB-182™) were evaluated according to the 
manufacturer's instruction using the In-Situ Cell 
Death Detection Kit (Roche, Branchburg, NJ, USA). 
Cells were seeded in six-well cell culture plates in 2 
mL medium with serum under 5% CO2 at 37°C. Cells 
were washed with PBS three times then exposed in 
the recommended media to 9 mM or 90 mM M-PFC 
NP. After 24 h incubation, cells were washed three 
times with PBS and then evaluated for apoptosis with 
TUNEL diagnostic kit (EMD Millipore, Billerica, MA). 
The nuclei were stained with 4',6'-diamidine-2'- 
phenylindole dihydrochloride (DAPI, Sigma Aldrich, 
St. Louis, MO). Cells were imaged microscopically 
with an Olympus inverted fluorescence microscope 
(Olympus (Beijing) Sales & Service Co., Ltd., Beijing, 
China). 
Flow cytometry assay 
Normal epithelium cell BEAS-2B were grown in 
the presence of 9 mM M-PFC NPs for 24 h. 
Trypsinized cells were harvested and washed in cold 
PBS(3×), then isolated by centrifugation (1273 g for 5 
min). Single cell suspensions were added to 
pre-chilled 75% ethanol and fixed at −20°C overnight. 
The cells were rinsed with phosphate buffer, 
resuspended, then post-fixed with Cell Cycle Assay 
KIT (Biyuntian Company, Shanghai, China). Flow 
cytometry was performed using a FACScan (Becton 
Dickinson, San Jose, CA) equipped with 488 nm and 
633 nm lasers. Samples were gated to exclude debris 
and clumps, and electronic compensation was used to 
remove residual spectral overlap. The experiment was 
repeated in triplicate and data were analyzed using 
MultiCycle software WinCycle 32 (Phoenix Flow 
Systems, Inc., San Diego, CA). 
Clinical pathology 
Animal protocols were performed in accordance 
with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of 
Health (NIH publication No. 85-23, revised 1996) and 
were approved and monitored by the Harbin Medical 
University and Washington University Animal Care 
and Use Committee, respectively. 
Clinical pathology was performed on two sets of 
KunMing white mice (20-25 g, n=15). Each cohort of 
animals was divided into five groups 





(n=3/treatment): (1) a sham group; (2) IV M-PFC NP 
(2.5 mL/kg, 0.9 g PFC/kg) sacrificed at 24 h; (3) 
bilateral IT M-PFC NP (2.5 mL/kg, 0.9 g PFC/kg) 
sacrificed at 24 h; (4) IV M-PFC NP (2.5 mL/kg, 0.9 g 
PFC/kg) sacrificed at 7 d; or (5) bilateral IT M-PFC NP 
(2.5 mL/kg, 0.9 g PFC/kg) sacrificed at 7 d. Blood 
samples were submitted for electrolytes, hematology, 
liver function and renal function. 
Rabbit Vx2 lung xenograft model 
The Vx2 tumors, a squamous carcinoma derived 
originally from Rous sarcoma virus tumor in rabbits 
[27], were surgically implanted into New Zealand 
white rabbits (2.0–2.5 kg) in the right lung proximate 
to the hilum. Rabbits were fasted 12 h prior to 
anesthesia. Atropine (0.05 mg/kg) was injected 
intramuscularly 15 min prior to anesthesia followed 
by 3% pentobarbital (30 mg/kg) via an indwelling ear 
vein catheter. Two or three Vx2 tumor fragments (1 
mm3 each) were implanted in the hind limb of a donor 
rabbit, and a tumor grew to a desirable size (~20 mm 
diameter) in 2 weeks. The tumor was surgically 
removed from the donor rabbit under general 
anesthesia (as above) and minced into 1 mm3 
fragments. The anesthetized recipient rabbit was 
positioned supine. The surgical area on the chest was 
shaved, prepped and draped. Under CT guidance, an 
18 ga needle was percutaneously inserted into the 
right lung and positioned in the right lobe proximal to 
the hilum. Two fragments of minced Vx2 tumor were 
implanted through a 20 ga aspiration needle. 
Following extraction of the needle, the incision point 
was disinfected and sterile dressings were applied. 
Rabbits recovered from anesthesia and were allowed 
food and water ad libitum. Two weeks after tumor 
implantation, CT (GE Discovery VCT64) was used to 
confirm tumor development and size. 
MRI Study 
Longitudinal relaxation time measurements and 
T1 mapping were performed using a GE W750 clinical 
3.0T scanner. 19F MR imaging was performed on a 
Philips Achieva 3.0T scanner. Relaxivity r1 was 
determined by linear fits of R1 versus [Gd]. 
Particulate concentration was calculated based on the 
total volume of NPs divided by single particle 
volume(4/3)πr3, where r was nominal particle size 
based on DLS testing. A T1w fast spin echo sequence 
(FSE) at ambient room temperature was used for 
scanning. 
Animals for T1 imaging were anesthetized with 
2% isoflurane. Vx2 rabbits were administered M-PFC 
NPs by IV or IT (n=3, 1 mL/kg, pre-saturated with 
O2), using a double-blind protocol. Coronal 1H MR 
images were acquired pre-contrast and subsequently 
at 1, 2, 3, 7, 12, 24, 48, 72 h using a facet joint coil. The 
MR imaging parameters were: T1w FSE sequence 
Echo Train Length:2, TE:9.3 ms, TR:1200 ms, slice 
thickness: 5 mm, field of view (FOV): 12×12, matrix 
size:288×256, flip angle:90°. For T1 mapping a T1 FSE 
sequence with the same parameters as above was 
employed except the flip angle was 111° and TEs were 
50, 100, 300, 500, 700, 900, 1200, 1500, 1800, 2100, 2500 
ms. 
For 19F imaging, the rabbits were anesthetized 
with Zoletil 50 solution by intramuscular injection 
(Virbac (Australia) Pty Limited, Milperra, Australia). 
An initial 1H acquisition for anatomical detail was 
performed using a fast gradient echo technique with 
the body coil (transmit/receive). Matrix: 244×195, 
FOV: 140 mm, reconstruction voxel size: 0.625 mm, 
TR/TE: 315ms/4.6ms, total scan duration: 02:04, 
reconstruction: 320×320, flip angle: 80°, NSA: 2. 
Fluorine imaging was performed with a 
MC-Rapid-BM-MN coil (RAPID Biomedical GmbH, 
Rimpar, Germany) using a 3D fast gradient echo 
technique with ultrashort TE (UTE) sequence: FOV: 
140 mm, TR/TE: 5.5ms/0.32ms, flip angle: 20°, slice 
number: 112, slice thickness: 1.25 mm, total scan 
duration: 04:47, reconstructed voxel size: 1.25 mm, 
matrix: 112×112, NSA: 2. The fluorine concentration of 
the reference phantom for 19F MR imaging was 0.65 
M. 
Histopathology and immunofluorescence  
Male New Zealand white rabbits (~2 kg, n=3) 
were anesthetized with intramuscular ketamine and 
xylazine. One hind leg was shaved, prepped under 
sterile conditions, and infiltrated with Marcaine. A 2-3 
mm3 rabbit Vx2 tumor fragment (squamous cell 
carcinoma, National Cancer Institute Tumor 
Repository, Frederick, MD, USA) was implanted at a 
depth of ~0.5 cm through a small incision into the 
popliteal fossa. Anatomical planes were closed and 
secured with a single absorbable suture. The skin was 
sealed with Dermabond skin glue. Animals were 
recovered by reversing the effect of ketamine and 
xylazine with yohimbine. After ~7 weeks, animals 
were imaged with fluoroscopy to confirm metastasis 
from the popliteal fossa to the lungs. Animals were 
anesthetized with isoflurane to effect, then a catheter 
was passed under fluoroscopy into the right lung and 
the M-PFC NP dose was instilled (1 mL/kg). The 
rabbits recovered and were sacrificed 12 h later for 
microscopic examination of the airway and tumor 
response to the IT treatment.  
The lung and tumor were harvested from the 
experimental animals, frozen in OCT and 
cryosectioned at 5 μm thickness. Routine staining 
including hematoxylin/eosin, CD68, CD31 and 





proliferating cell nuclear antigen (PCNA) were 
performed. Nuclei were stained with DAPI. M-PFC 
NPs were observed with fluorescence microscopy 
(Olympus (Beijing) Sales & Service Co., Ltd., Beijing, 
China). 
In vivo biodistribution experiment 
Biodistribution of PFC NPs (1 mL/kg) delivered 
IT or IV was performed in two groups of normal adult 
KunMing white mice weighing 20-25 g 
(n=3/treatment). At 0.5, 2, 6, 24 and 48 h post 
treatment, mice were sacrificed and lung, liver, 
kidneys, spleen, heart, brain, intestine were excised 
and imaged ex vivo with a Xenogen IVIS spectrum 
imaging system (Perkin Elmer, Waltham, MA) using 
identical imaging settings (excitation 535 nm, 
emission DsRed, exposure time: 1s, binning factor: 2, 
F number: 4, FOV: 12.5) for all acquisitions.  
Results  
Synthesis and physical-chemical 
characterization of perfluorocarbon 
nanoparticles 
M-PFC NPs were comprised of 20% (v/v) 
perfluoro-15-crown-5-ether (PFCE), 2% (w/v) lipid 
surfactant commixture, which is endogenous to the 
lung as surfactants, 1.7% (w/v) glycerin and water 
representing the balance. The lipid surfactant 
included 80 mol% DPPC, 10 mol% cholesterol, 5 mol% 
Gd-DTPA-phosphatidylethanolamine (Gd-DTPA- 
DPPE), 0.1 mol% rhodamine phospholipid, and 4.9 
mol% dipalmitoylphosphatidylglycerol (DPPG). The 
average nominal hydrodynamic diameter of the 
M-PFC nanoparticles determined by DLS was 132±6 
nm with polydispersity index 0.14±0.01 and zeta 
potential of -42±4 mV. The morphology and height of 
the sample obtained by atomic force microscopy in 
standard tapping mode demonstrated a soft spherical 
particle on a surface with height and width estimates 
of 137±16 nm and 62±13 nm, respectively. The MR 
magnetic properties of ionic and particulate 
relaxivities (r1) of M-PFC were 3.5 mM-1s-1 and 20,450 
mM-1s-1, respectively. The use of Gd-DTPA-PE, 
provided enhanced 1H r1 relaxivity relative to 
Gd-DTPA-bisoleate (Gd-DTPA-BOA) studied 
previously [28], but the overall 1H r1 was lower than 
prior PFC NP that included 20-30 mol% 
gadolinium-lipid chelate (Figure 1 and Supplemental 
Figure S1). 
As previously mentioned, PFCs are chemically 
inert molecules with weak intramolecular interactions 
that permit significant quantities of many gases, 
including oxygen and carbon dioxide, to be physically 
dissolved [29, 30]. The capability to dissolve and 
release oxygen was preserved and demonstrated for 
the M-PFC NP emulsion as referenced to nanopure 
water using a digital multi parameter meter (Multi 
3430 WTW, Germany) coupled with an O2 sensor 
(CellOx 325, WTW, Germany). Oxygen content in 
pure water and M-PFC NP (20%, v/v%) solution were 
determined at baseline with slowly bubbled 100% 
oxygen preoxygenation (5 min) followed by serial O2 
assessments every 5 min for 30 min to measure O2 
release (Supplemental Figure S2). The oxygen 
content of the M-PFC NP was higher than nanopure 
water; however, O2 rate of loss from the emulsion was 
rapid and paralleled that of water. 
The good biocompatibility and minimal 
cytotoxicity of perfluorocarbon emulsions with 
phospholipid surfactants were again appreciated 
following direct exposure of human bronchial 
epithelial (BEAS-2B) and human lung squamous 
carcinoma (H520) cells to M-PFC NP at low (9 mM) 
and high (90 mM) concentrations. TUNEL staining 
revealed no evidence of apoptosis in either cell type at 
either concentration. Further, incubation of M-PFC 
NP (9 mM) had negligible impact on the cell cycle 
progression (stages G0/G1, G2, S) of epithelial cells 
over 24 h (Supplemental Figure S3 and S4). 
Clinical pathologic circulating biomarkers 
including electrolytes, liver function, renal function, 
and hematology of healthy mice given IV of M-PFC 
NP did not differ obviously from control counterparts 
receiving buffered saline. Intratracheal delivery of 
M-PFC NP elicited no changes in clinical pathology 
markers after 24 h or 168 h (7 d) of exposure 
(Supplemental Tables S1 and S2). 
1H and 19F MRI of M-PFC NP following IT or IV 
administration 
Rabbits bearing 14-day Vx2 tumors received 
M-PFC NP (1 mL/kg) via catheter directly into the 
right lung IT or by IV through ear vein injection. IT 
delivered M-PFC NP remained in the right lung for 72 
h with no observed effects on animal behavior or 
respiratory function. 1H MR of the rabbit tumors and 
nearby muscle tissue following IV and IT M-PFC NP 
administration elucidated the localization of the 
particles in and around the tumors (Figure 2). Small 
increases in tumor R1 following IV M-PFC NP were 
detected for 2 h post injection, relating to blood pool 
contrast effects, but these changes were not measured 
beyond 3 h. IV administration of the M-PFC NP 
maximally increased normalized R1 time in nearby 
muscle tissue at 30 min post treatment, then the signal 
steadily declined toward baseline during the next 12 
h. In contradistinction, IT administration of M-PFC 
NP markedly increased tumor R1 response 
progressively over 12 h and this strong enhancement 





persisted for 72 h. These data suggested that the 
M-PFC NP given IT accumulated slowly and 
remained confined locally in the lung Vx2 tumors; 
whereas, the same particles given IV failed to 
effectively extravasate into the cancer. Moreover, the 
strong increase in tumor 1H R1 with M-PFC NP given 
IT suggest that the payload of particles accumulated 
in the lesion was large, particularly since the 1H 
relaxivity of the M-PFC NP studied was low. These 
superior MR data clearly suggest a theranostic 
potential for IT PFC NP administration in lung cancer.  
 
 
Figure 1. Physicochemical characterization of multifunctional perfluorocarbon nanoparticles. (A) Schematic representation of the structure of M-PFC NPs. (B) 
UV-Vis absorption spectra of PFC NPs with and without inclusion of rhodamine-PE. (C) DLS nominal hydrodynamic diameter of the multifunctional PFCs in aqueous 
solution was ~132 nm with stability across a wide pH range (4-12). (D) Particle morphology and height obtained from AFM. (E) T1w MR images. (F) T1map images 
as a function of Gd ion concentration; (G)19F phantom images for decreasing PFC concentration (From 1 to 5: 332, 265, 199, 132, 66 mM); 1H R1 as a function of (H) 
Gd ion and (I) particulate concentration. Slopes provide r1; (J) Linear fit between 19F signal intensity and PFC concentration. 






Figure 2. Representative images of in vivo T1w MRI after IT delivery of M-PFC NPs. (A) T1 color mapped MR images normalized to baseline; T1w MR images of (B) 
sagittal view, (C) coronal view, (D) transverse view; (E) and (F), the quantitative calculation of the enhancement at tumor(E) and muscle(F) sites and their specific value 
of R1 after different administration points (the error bars represent the standard deviations of three independent measurements of the same group). 
 
Pulmonary 19F imaging of the tumor with the 
M-PFC NP using the same IT delivery protocol 
mirrored the marked 1H R1mapping results closely. 
19F signal was visually prominent in the Vx2 tumor at 
1 h and this strong signal persisted over 72 h, as 
shown in Figure 3. 19F imaging with paramagnetic 
PFC nanoparticles is inherently less sensitive than 1H 
imaging due to the relative paucity of fluorine atoms 
per voxel and lower NMR sensitivity of 0.83. 
However, the magnitude of the 19F signal can be 
enhanced when gadolinium-lipid chelates, such as 
Gd-DTPA-BOA, that position the metal very close to 
the PFC core are included in the lipid surfactant [22, 
31-33]. In the present study the low level of 
Gd-DTPA-PE placed the metal further away from the 
PFC molecules into the surrounding water, providing 
minimal benefit to the 19F signal. 
M-PFC NP utilized perfluorocrown ether (PFCE) 
(15:5) to maximize 19F signal by increasing the number 
of iso-resonant fluorine atoms and to offset the 
possibility that the particles localizing in the tumor 
would be too few to detect. Yet, the tumor 1H R1 
increase achieved with M-PFC NP was very high, as 
was the 19F signal. These data showed that intact 
M-PFC NP entered the tumor with the surfactant and 
PFC core maintained together. 
Microscopy of implanted and metastatic Vx2 
lung cancer 
Consistent with previous studies in which 
paramagnetic PFC nanoparticles, both targeted and 
non-targeted, were administered intravenously to 
rabbits bearing Vx2 tumors in the popliteal 
fossa[24-26], rabbits with pulmonary tumors given 
fluorescent M-PFC NP IV showed negligible 
permeation of the particles into the cancer (Figure 4). 
This result corroborated the lack of persistent MR 
signal appreciated in the lung following M-PFC NP IV 
treatment. In contradistinction, microscopy of the 
pulmonary Vx2 cancer 72 h after IT M-PFC NP 
revealed deep penetration into the tumor with very 
dense particle coating around the tumor and stromal 
cells. By comparison, adjacent tumor-free lung tissue 
was non-consolidated and showed no evidence of 
fluorescent M-PFC NPs in the parenchyma (Figure 
4A). The surfactant fluorescent dye, which could be 
considered as a surrogate therapeutic biomarker, 
labeled most of the cells in the lesion. 
A second cohort of rabbits (n=3) with Vx2 tumor 
implanted in the popliteal fossa metastasized 
spontaneously to the lung in 7 weeks. Fluorescent 
M-PFC NP were delivered IT into the right bronchus 





and remained for 12 h. Following sacrifice, the 
pulmonary airways were excised, sectioned and 
reviewed microscopically. Segments of the airway 
without Vx2 tumor metastases were devoid of 
nanoparticles and without inflammation. In other 
regions, metastatic tumors were observed adjacent to 
the airways and fluorescent M-PFC NP were 
distributed densely throughout the tumor (Figure 
4B). The surrounding airway epithelium had minimal 
fluorescent dye uptake. Possibly the mucous barrier 
and ciliary clearance mechanism that protectively 
transports foreign particles from the lungs constituted 
a barrier between the particle lipid surface and 
epithelial cell membrane. 
In both models, IT M-PFC NP penetrated deep 
into the Vx2 tumors and transferred the fluorescent 
lipid dye to cancer and other cells seen. Although the 
M-PFC NP administered IT were not targeted, their 
dense accumulation and prolonged contact with cells 
in the tumor led to a similar end result. Interestingly, 
the central necrotic cores of these metastatic tumors 
were devoid of fluorescent M-PFC NP, suggesting a 
difference in lung tumor development between 
implanted cancer pieces and spontaneously 
metastatic cells. 
Biodistribution of nanoparticles given 
intratracheal versus intravenous 
Tissue biodistribution study of fluorescent 
M-PFC NP (Figure 5) was studied in mice using a 
Xenogen IVIS imaging system, recognizing that 
rodents, unlike humans or rabbits, uniquely excrete 
nanoparticles rapidly into the small intestine via the 
biliary system [34]. As has been long appreciated for 
PFC NP [35, 36], M-PFC NPs given IV distributed to 
the spleen, liver and intestine at 30 min with little or 
no appreciable signal in the heart, lung or brain, 
which is also consistent with previous studies[37]. 
Between 6 and 24 h, IV M-PFC NP concentrations in 
the liver and spleen declined, with the fluorescence 
signal shifting to the bowel. By comparison, IT M-PFC 
NP distributed into the airway and lung with no 
systemic accumulation observed in the liver, spleen, 
or intestine over the course of the study. These data 
are consistent with MR imaging data in rabbits and 
suggest that IV administered M-PFC NP do not easily 
extravasate into tumors [24-26]; conversely IT 
administered particles were constrained within the 
tumor. Ultimately, bioelimination of PFC NP, whether 
administered IV or IT, eventually occurs through 
pulmonary exhalation of volatilized PFC [38], with 
the surfactant lipid components metabolized or 
excreted from the body. The benign PFC expiratory 
clearance mechanism combined with the potential to 
dissolve and locally release inspired oxygen from 
within the tumor suggests an advantage for IT PFC 
NP. 
Discussion 
Lung cancer often presents in its late stages with 
cough and hemoptysis associated with tumor erosion 
into the airway. The prognosis for these patients is 
grim and palliative therapy often has limited benefit. 
Yet, in these poor prognosis situations, tumor 
disruption through the airway epithelial barrier may 
offer uncommon drug access into the lesion via 
intratracheal delivery. Typically, pulmonary 
inhalation of drugs and particles, whether therapeutic 
or via environmental exposure, can elicit pulmonary 
inflammation and respiratory dysfunction. Although 
intended for local delivery, IT delivery of 
nanoparticles frequently permeates further into the 
circulation, decreasing the level of therapy retained in 
the lung and increasing the risk of systemic off-target 
effects [39]. As an example, the orotracheal delivery of 
ultrasmall gadolinium oxide nanoparticles was 
shown to effectively penetrate into lung tumor but 
then continued to diffuse into the circulation and 
subsequently collected in the kidney [40]. Some 
inhaled particles, such as large iron oxide 
nanoparticles (100 nm), elicit strong inflammatory 
responses and elevated chemokine secretions [41]. 
Titanium oxide (TiO2) nanoparticles, known to cause 
renal fibrosis when injected systemically, were found 
to elicit dose-dependent pathological changes in the 
kidney via IT delivery as well as emphysema-like 
lung injury [42, 43]. Clearly, the intended localized 
high dose and safety benefits attributed to IT 
nanoparticle delivery can be compromised when the 
minute size of these agents permits penetration into 
the systemic circulation or when the chemical 
composition is inflammatory. 
Perfluorocarbons inherently have high 
biocompatibility and a capacity to dissolve oxygen 
that was dramatically demonstrated by 
liquid-ventilation, i.e., liquid breathing, in rodents in 
1966 [44]. Continued research with PFC nanoparticles 
led to a seminal clinical demonstration of improved 
pulmonary function in neonatal infants suffering with 
respiratory distress syndrome in 1996 [15]. These 
fragile neonates receiving intratracheal PFC NP 
experienced improved respiratory function with 
negligible adverse effects. Over the last 25 years, PFC 
NPs have been extensively explored in both 
preclinical and clinical realms. Applications involving 
IV administration of PFC NP include blood pool 
imaging, inflammation imaging, cell tracking, 
thrombus detection and treatment, angiogenesis 
imaging and drug delivery in cancer, atherosclerosis, 
and rheumatoid arthritis models, etc. [45-48]. 






Figure 3. Dynamic monitoring of 19F-MR enhancement at different time points post IT delivery of the M-PFC NPs. Image slices were acquired at different time points 
and examples selected to depict similar cardiothoracic regions.  
 
Figure 4. (A) Microscopy of rabbits receiving in situ surgical implantation, following IT treatment. The upper row represents the typical images harvested from lung 
tumor 72 h after MR study. Fluorescence microscopy images of tumor tissue with DAPI stained nuclei (blue) and Rhod B(red) fluorescence from M-PFC NP. Normal 
tissue from the same rabbit with no M-PFC NP signal (scale bars = 100 μm). (B) Microscopic imaging of metastatic carcinoma Vx2 tumor model. While the left lung 
showed low tumor burden, the right lung had tumors with high density M-PFC NP signal (red) around the tumor periphery. H&E staining of lung tumor (white box, 
expanded) revealed a necrotic core (arrows), which is also indicated by a star in the lower magnification image. CD68 macrophages were noted around the tumor 
capsule. PECAM stained blood vessels were also mostly peripheral around the tumor capsule (arrows). Proliferating PCNA positive cells were best observed within 
the metastatic tumor and around its capsule. 






Figure 5. The biodistribution of M-PFC nanoparticles with time-dependent isolated organs as seen using the NIRF imaging technique. (A) Intratracheal delivery; (B) 
intravenous injection. (scale bars=1 cm) 
 
In the present study, the high biocompatibility, 
ideal size, oxygen dissolving capacity and natural 
bioelimination via exhalation contributed to the 
success of M-PFC NP in the Vx2 rabbit lung tumor 
model. As evidenced by 1H and 19F MR imaging, the 
IT M-PFC NP penetrated into the growing Vx2 tumor, 
slowly and progressively over 12 h and persisted for 
72 h. The magnitude and persistence of M-PFC NP via 
intratracheal delivery into the tumor was dramatically 
better than the minimal and transient MR T1 signal 
response noted at 2 h following IV injection. 
Moreover, IT M-PFC NP were essentially confined to 
the cancer, lung and airways, whereas, the 
biodistribution of IV M-PFC NP extended beyond 
with systemic accumulation in the liver and spleen.  
Extravascular distribution of nanoparticles into 
tumors following intravenous injection remains a 
significant barrier to the clinical translation of 
nanotechnology [49]. Although some particles are 
capable of penetrating beyond the circulation and into 
the tumor, inhomogeneous distribution within the 
lesion with large portions of the cancer unaffected is 
common [50]. Intratumoral delivery by IT M-PFC NP 
had very homogeneous distribution, excluding only 
the necrotic regions. In each animal, the IT fluorescent 
M-PFC NP densely coated the tumor cells and their 
microenvironment, which was evidenced by the 
strong T1 shortening and prominent 19F signals 
measured with MRI.  
The prolonged tumoral persistence of the 19F and 
1H signal administered IT also reflects the very long 
biological half-life of PFCE (250d, 9.4T) as compared 
with perfluorooctylbromide (PFOB, 12d, 9.4T) used 
previously in clinical studies [51]. In humans, the 
biological half-life estimate for PFOB is typically cited 
as 3-4 d, while PFCE intrapulmonary persistence is 
clinically too long (>60 d) [52]. Recently, 19F 
neovascular molecular imaging studies at 3T (clinical) 
utilized αvβ3-targeted PFOB nanoparticles to detect 
the sparse αvβ3-intergrin expression of pulmonary 
neovasculature in rat models of acute lung ischemia 
and asthma [53-55]. These data considered in 
combination with the strong serial 1H/19F data 
presented in this report suggest that substitution of 
PFCE with PFOB would not compromise the 
theranostic potential of the nanoplatform approach. 
Although the treatment of lung cancer was 
beyond the scope of this proof-of-concept imaging 
study, the potential for effective lung cancer treatment 
with IT delivered PFC NP was suggested by the broad 





transfer of rhodamine-lipid dye to intratumoral cells 
observed with microscopy. The formation of these 
irreversible lipid fusion complexes facilitates the 
delivery of drug payloads into cells via "contact 
facilitated drug delivery" [56]. Moreover, the dense 
delivery of continuously oxygenated PFC NP within 
an otherwise hypoxic tumor may offer potent 
radio-sensitization for focal radiation or PDT therapy 
guided by 19F-MRI [57-60]. The use of therapeutic 
drugs in combination with IT administered PFC NP 
may be a highly effective delivery approach for lung 
cancer warranting further research. 
Conclusion 
Lipid-encapsulated M-PFC NP were 
administered via intratracheal delivery into rabbits 
bearing pulmonary Vx2 tumors implanted surgically 
or formed by metastasis. Enhanced intratumoral 
penetration of intact paramagnetic PFC nanoparticles 
by IT administration was demonstrated for the first 
time by 19F and 1H MR using clinical 3T scanners. The 
PFC particles persisted for over 72 h in vivo without 
adverse effects on rabbit behavior or respiration. 
Fluorescence microscopy corroborated that IT M-PFC 
NP permeated deeply and distributed widely 
throughout the tumors. In contradistinction, IV 
M-PFC NP did not extravasate into the lung cancers 
and provided much lower transient tumor contrast 
enhancement, consistent with a blood pool effect. By 
the IT route, M-PFC NP uptake was confined to the 
Vx2 cancer without significant permeation into the 
general circulation. By comparison, IV administration 
of M-PFC NP resulted in transient enhancement of 
highly vascular muscle tissues with typical RES 
clearance by the liver and spleen. This 
proof-of-concept study returns the focus of PFC NP 
delivery from intravenous applications to 
intratracheal use to address the unmet challenges 
posed by lung cancer. 
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